

Attachment 5f

Evaluating the Impact of Training and Technical Assistance (TTA) Programs on NCCCP Efforts – Web-based Survey (MS Word format)

CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-1193).

INTRODUCTION

Thank you for participating in this survey about CDC's Training and Technical Assistance (TTA) Program to support comprehensive cancer control programs.

Please respond to the following questions according to your individual experience receiving TTA from the National Comprehensive Cancer Control Program (NCCCP) TTA providers: American Cancer Society (ACS) and George Washington University Cancer Center (GWCC). When responding to this assessment, please reflect on the TTA-related activities that occurred **between [insert date] and [insert date]**.

You may save your responses at any time and return later to complete the survey. Use the "<<Previous Page" and "Next Page >>" buttons to move through the survey.

SURVEY LEGEND

☐ = Single Choice Button

☐ = Multiple Choice Check Box

Section 1. Participant Characteristics

[ASK ALL]

SECTION 1. Participant Characteristics

The purpose of the following questions is to collect information on your jurisdiction and program affiliation and your current role with the comprehensive cancer control program.

[ASK ALL]

1. Select the comprehensive cancer control program with which you are affiliated.* [DROP DOWN]

- 1, Alabama State Department of Public Health
- 2, Alaska Department of Health
- 3, Alaska Native Tribal Health Consortium
- 4, American Indian Cancer Foundation
- 5, American Samoa Government Department of Health
- 6, Arizona Department of Health Services
- 7, Arkansas Department of Health
- 8, California Department of Health
- 9, Cherokee Nation
- 10, Colorado Department of Public Health
- 11, Commonwealth Health Care Corporation of the Northern Mariana Islands
- 12, Connecticut Department of Public Health
- 13, Delaware Department of Health

*Must provide answer

- 14, District of Columbia Department of Health
- 15, Federated States of Micronesia Department of Education
- 16, Florida Department of Health
- 17, Fond Du Lac Band of Lake Superior Chippewa
- 18, Georgia Department of Human Resources
- 19, Great Plains Tribal Leaders Health Board
- 20, Guam Department of Public Health
- 21, Hawaii State Department of Health
- 22, Idaho Department of Health and Welfare
- 23, Illinois Department of Health
- 24, Indiana Department of Health
- 25, Iowa Department of Health and Human Services
- 26, Kansas Department of Health
- 27, Louisiana State University
- 28, Maine Department of Health
- 29, Maryland Department of Health
- 30, Massachusetts Department of Health
- 31, Michigan Department of Health and Human Services
- 32, Minnesota Department of Health
- 33, Mississippi Department of Health
- 34, Missouri Department of Health
- 35, Montana Department of Public Health and Human Services
- 36, Nebraska Department of Health and Human Services
- 37, Nevada Department of Health and Human Services
- 38, New Hampshire Department of Health
- 39, New Jersey Department of Health
- 40, New Mexico Department of Health
- 41, New York State Department of Health
- 42, North Carolina Department of Health
- 43, North Dakota Department of Health
- 44, Northwest Portland Area Indian Health Board
- 45, Ohio Department of Health
- 46, Oklahoma State Department of Health
- 47, Oregon Health Authority
- 48, Pennsylvania Department of Health
- 49, Republic of Palau Ministry of Health
- 50, Republic of the Marshall Islands Ministry of Health and Human Services
- 51, Rhode Island Department of Health
- 52, South Carolina Department of Health
- 53, South Dakota Department of Health
- 54, South Puget Intertribal Planning Agency

- 55, Tennessee Department of Health
- 56, Texas Department of Health
- 57, University of Kentucky
- 58, University of Puerto Rico Comprehensive Cancer Center
- 59, University of West Virginia
- 60, Utah Department of Health
- 61, Vermont Department of Health
- 62, Virgin Islands Department of Health Group
- 63, Virginia Department of Health
- 64, Washington State Department of Health
- 65, Wisconsin Department of Health
- 66, Wyoming Department of Health
- 77, Other, please specify: {1A}

[DISPLAY ONLY IF 1.77=1]

1A. Please specify "Other" if the comprehensive cancer control program with which you are affiliated is not listed:*

[TEXT BOX]

[ASK ALL]

2. Please select the type of organization you work with for the comprehensive cancer control program. Select one.

- 1, State government agency (including the District of Columbia)
- 2, Territorial government agency
- 3, Local government agency
- 4, American Indian or Alaska Native tribal government agency
- 5, Private college or university
- 6, State controlled institution of higher education
- 7, Not for profit organization
- 77, Other, please specify: {2A}

[DISPLAY ONLY IF 2.77=1]

2A. Please specify "Other" organization type:

[TEXT BOX]

[ASK ALL]

3. Which best describes your current role with the comprehensive cancer control program and/or coalition? Select all that apply.

- 1, Program Director
- 2, Program Manager
- 3, Policy Analyst
- 4, Evaluator
- 5, Program Staff

- 6, Partner
- 7, Coalition Coordinator
- 8, Coalition Member
- 77, Other, please specify: {3A}

[DISPLAY ONLY IF 3.77=1]

3A. Please specify "Other" primary role within your comprehensive cancer control program and/or coalition:

[TEXT BOX]

Section 2. Awareness of TTA Services Available

[ASK ALL]

SECTION 2. Awareness of TTA Services Available

The following questions ask about your awareness of **TTA resources available from two NCCCP TTA providers: American Cancer Society (ACS) and George Washington University Cancer Center (GWCC)**. For the purpose of this assessment, TTA refers to any individualized, small group, or large group activity or resource that provides advice, assistance, or training pertaining to program development, implementation, maintenance, or evaluation of comprehensive cancer control programs funded by CDC. When answering the following questions, please consider only TTA provided by ACS and GWCC or their partners.

[ASK ALL]

4. Are you aware of TTA services available to NCCCP recipients and partners? Select one.*

- 1, Yes
- 2, No [SKIP to 7]

[ASK IF 4.1 = YES]

5. Which of the following TTA modalities are you aware of? Select all that apply.

- 1, Webinars
- 2, Emails or newsletters
- 3, In-person trainings
- 4, Asynchronous trainings
- 5, One-on-one calls
- 6, Small group/peer-to-peer learning
- 7, Toolkits & briefs
- 8, Site visits
- 9, Communities of Practice/Learning Communities
- 10, Online resources
- 77, Other, please specify: {5A}

[DISPLAY ONLY IF 5.77=1]

5A. Please specify "Other" types of TTA you are aware of:

[TEXT BOX]

[ASK IF 4.1 = YES]

6. How do you become aware of the TTA resources available for cancer prevention and control efforts? Select all that apply.

- 1, Via email newsletter or announcement from TTA provider
- 2, Via communications from CDC (e.g., program consultant, program evaluator, listserv)
- 3, Via communications from a professional association
- 4, Via communications from other organization, please specify: {6A}
- 5, During workshops or webinars
- 6, At conferences or in-person events

- 7, Via peer recommendations or word of mouth
- 8, From direct outreach from TTA providers
- 9, Social media
- 77, Other method, please specify: {6B}

[DISPLAY ONLY IF 6.4=1]

6A. Please specify “other organization” communicating about TTA resources:
[TEXT BOX]

[DISPLAY ONLY IF 6.77=1]

6B. Please specify “Other method” of awareness about TTA resources:
[TEXT BOX]

[ASK ALL]

7. Select your preferred method of learning about TTA resources available for cancer prevention and control efforts. Select one.

- 1, Via email newsletter or announcement from TTA provider
- 2, Via communications from CDC (e.g., program consultant, listserv)
- 3, Via communications from a professional association
- 4, Via communications from other organization, please specify: {7A}
- 5, During workshops or webinars
- 6, At conferences or in-person events
- 7, Via peer recommendations or word of mouth
- 8, From direct outreach from TTA providers
- 9, Social media
- 77, Other method, please specify: {7B}

[DISPLAY ONLY IF 7.4=1]

7A. Please specify “other organization” communicating about TTA resources:
[TEXT BOX]

[DISPLAY ONLY IF 7.77=1]

7B. Please specify “Other method” of awareness about TTA resources:
[TEXT BOX]

Section 3. Exposure/Receipt of TTA

SECTION 3. Exposure/Receipt of TTA

The purpose of the following question(s) is to collect information on the TTA you received from NCCCP TTA providers. As a reminder, please reflect on TTA-related activities that occurred between [insert start date of response period] and [insert end date of response period].

[ASK IF 4.1 = YES]

8. Between [insert date] and [insert date], have you received or participated in any TTA from the following TTA providers? Select one.*

- 1, Yes, from American Cancer Society (ACS) only
- 2, Yes, from George Washington University Cancer Center (GWCC) only
- 3, Yes, from both ACS and GWCC
- 0, Did not receive or participate in TTA from any of the above providers

[ASK IF 8.0=YES]

8a. Please describe why you did not receive or participate in TTA from NCCCP TTA providers, including any barriers to accessing or receiving TTA.

[TEXT BOX]

[End Survey and go to closing if 8.0=YES]

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

9. Select the TTA activities from NCCCP TTA providers that you participated in between [insert start date of response period] and [insert end date of response period]. Select all that apply.

- 1, Facilitated Leadership for Cancer Coalitions (FLCC) Refresher Sessions
- 2, Webinars
- 3, Cancer screening briefs
- 4, Online Academy Ambassador Programs
- 5, GWCC Online Academy
- 6, GWCC Online Academy Ambassador Program
- 7, Micro-learning modules through the ACS Coalition University
- 8, Cancer Awareness Toolkits
- 9, In-person training/workshops or TA
- 10, Micro-learning modules
- 11, Networking sessions
- 12, Communities of Practice or Learning Communities, please specify: {9A}
- 77, Other TTA activity type, please specify: {9B}

[DISPLAY ONLY IF 9.12=1]

9A. Please specify in which Communities of Practice or Learning Communities you participated:

[TEXT BOX]

[DISPLAY ONLY IF 9.77=1]

9B. Please specify "Other" TTA activity type:

[TEXT BOX]

Section 4. Description of TTA Received

SECTION 4. Description of TTA Received

The purpose of the following question(s) is to collect information on the type of TTA you received from NCCCP TTA providers between [insert start date of response period] and [insert end date of response period].

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

10. Please select the TTA modalities you received between [insert start date of response period] and [insert end date of response period] . Select all that apply.*

- 1, Webinars
- 2, Emails or newsletters
- 3, In-person trainings
- 4, Asynchronous trainings
- 5, One-on-one calls
- 6, Small group/peer-to-peer learning
- 7, Toolkits & briefs
- 8, Site visits
- 9, Communities of Practice/Learning Communities
- 10, Online resources, please specify: {10A}
- 77, Other TTA, please specify: {10B}

[DISPLAY ONLY IF 10.10=1]

10A. Please specify "Online Resources" received:*

[TEXT BOX]

[DISPLAY ONLY IF 10.77=1]

10B. Please specify "Other" types of TTA received:*

[TEXT BOX]

[PAGE BREAK]

[ASK IF 10=1,2,3,4,5,6,7,8, 9, 10, 11]

11. Please select the topics of TTA you received between [insert start date of response period] and [insert end date of response period]. Select all that apply.*

- 1, Coalition functioning
- 2, Primary prevention: Alcohol
- 3, Primary prevention: Environmental exposure
- 4, Primary prevention: Hepatitis B transmission or vaccination
- 5, Primary prevention: Human papillomavirus (HPV)
- 6, Primary prevention: Nutrition
- 7, Primary prevention: Obesity/overweight
- 8, Primary prevention: Physical activity
- 9, Primary prevention: Radon
- 10, Primary prevention: Sun/UV exposure
- 11, Primary prevention: Tobacco

- 12, Primary prevention: Other types of risk or protective factors, please specify: {11A}
- 13, Screening and early detection: General cancer
- 14, Screening and early detection: Breast cancer
- 15, Screening and early detection: Cervical cancer
- 16, Screening and early detection: Colorectal cancer (CRC)
- 17, Screening and early detection: Gynecological cancer
- 18, Screening and early detection: HPV-related cancers
- 19, Screening and early detection: Liver cancer
- 20, Screening and early detection: Lung cancer
- 21, Screening and early detection: Oral cancer
- 22, Screening and early detection: Ovarian cancer
- 23, Screening and early detection: Prostate cancer
- 24, Screening and early detection: Skin cancer
- 25, Screening and early detection: Other types of cancer, please specify: {11B}
- 26, Survivorship: Survivors
- 27, Survivorship: Caregivers, family members, support system
- 42, Survivorship: Palliative care and hospice
- 28, Policy, systems, and environmental change strategies
- 29, Psychosocial and behavioral change
- 30, Community clinical linkages
- 31, Population reach strategies
- 43, Rural populations (e.g., improving access, adapting programs or content, addressing rural-specific barriers)
- 32, Health for all
- 33, Evaluation and quality improvement
- 34, Establishing and building sustainable partnerships
- 35, Maintaining partnerships
- 36, Building sustainable programs
- 37, Using secondary (i.e., surveillance) data to inform program planning
- 38, Using secondary (i.e., surveillance) data to inform program evaluation
- 39, Addressing high programmatic staff turnover (e.g., retention strategies, succession planning)
- 40, Workforce development
- 41, Stigma
- 77, Other topics, please specify: {11C}

[DISPLAY ONLY IF 11.12=1]

11A. Please specify the types of risk or protective factors that you received TTA on as it relates to "Primary prevention: Other types of risk or protective factors":*

[TEXT BOX]

[DISPLAY ONLY IF 11.25=1]

11B. Please specify the types of cancer that you received TTA on as it relates to "Screening and early detection: Other types of cancer":*

[TEXT BOX]

[DISPLAY ONLY IF 11.77=1]

11C. Please specify "Other" TTA topics:
[TEXT BOX]

Section 5. TTA Influence on Strategies and Activities

SECTION 5. TTA Influence on strategies and activities

In this section, please share how the TTA offerings you received or engaged with from NCCCP TTA providers influenced **your ability** to promote and implement priorities, strategies, and activities for your comprehensive cancer control program.

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

12. To what extent has the TTA you received between [insert start date of response period] and [insert end date of response period] helped improve **your ability** to use the following strategies?

		77	88	0	1	2	3
		N/A	Don't know	Not at all	Small extent	Moderate extent	Great extent
12A	Enhance National Program of Cancer Registries (NPCR) data quality, completeness, use, and dissemination	0	0	0	0	0	0
12B	Use surveillance systems and population-based surveys to assess cancer burden and inform programmatic efforts	0	0	0	0	0	0
12C	Support partnerships for cancer control and prevention	0	0	0	0	0	0
12D	Deliver screening and implement evidence-based interventions (EBIs)	0	0	0	0	0	0
12E	Conduct program monitoring and evaluation	0	0	0	0	0	0

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

13. Of the TTA you participated in between [insert start date of response period] and [insert end date of response period], which TTA activities had the most impact on **your ability** to use the above strategies? Select all that apply.

- 1, FLCC Refresher Sessions
- 2, Webinars
- 3, Cancer screening briefs
- 4, Online Academy Ambassador Programs
- 5, GWCC Online Academy

*Must provide answer

- 6, GWCC Online Academy Ambassador Program
- 7, Micro-learning modules through the ACS Coalition University
- 8, Cancer Awareness Toolkits
- 9, In-person training/workshops or TA
- 10, Micro-learning modules
- 11, Networking sessions
- 12, Communities of Practice or Learning Communities, please specify: {13A}
- 77, Other TTA activity type, please specify: {13B}

[DISPLAY ONLY IF 13.12=1]

13A. Please specify in which Communities of Practice you participated:

[TEXT BOX]

[DISPLAY ONLY IF 13.77=1]

13B. Please specify "Other" TTA activity type:

[TEXT BOX]

[PAGE BREAK]

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

14. To what extent has the TTA you received between [insert start date of response period] and [insert end date of response period] helped improve your ability to conduct the following activities?

		77	88	0	1	2	3
		N/A	Don't know	Not at all	Small extent	Moderate extent	Great extent
14A	Use data to monitor cancer risk factors, incidence, and mortality	0	0	0	0	0	0
14B	Use cancer incidence and mortality data for program planning (e.g., to revise/update cancer control plans, select program priorities, set program baseline and targets)	0	0	0	0	0	0
14C	Share data to educate policymakers, partners, and the public about the people and places that are most impacted by cancer	0	0	0	0	0	0
14D	Collaborate with internal and external partners to set and report on annual and five-year objectives	0	0	0	0	0	0

*Must provide answer

		77	88	0	1	2	3
		N/A	Don't know	Not at all	Small extent	Moderate extent	Great extent
14E	Conduct policy scans to identify facilitators and barriers to cancer prevention, screening, and survivorship	0	0	0	0	0	0
14F	Use data to identify and collaborate with populations and geographic locations with the greatest burden	0	0	0	0	0	0
14G	Convene and maintain a multisectoral cancer control coalition	0	0	0	0	0	0
14H	Establish formal agreements with the cancer control coalition, partner organizations, and community members assuring their commitment to achieving NCCCP priorities/outcomes	0	0	0	0	0	0
14I	Provide staffing and support for coalition engagement	0	0	0	0	0	0
14J	Use data to implement a suite of interventions to advance program priorities that expand reach and make the greatest impact	0	0	0	0	0	0
14K	Identify short-, intermediate-, long-term strategies that complement each other and work synergistically to achieve 5-year objectives	0	0	0	0	0	0
14L	Select evidence-based interventions for strategies based on available research, coalition buy-in, resources for implementation, and promising program practice	0	0	0	0	0	0
14M	Create a performance measurement plan to report short, intermediate, and long-term outcomes	0	0	0	0	0	0
14N	Develop and implement annual evaluation plans	0	0	0	0	0	0

*Must provide answer

		77	88	0	1	2	3
		N/A	Don't know	Not at all	Small extent	Moderate extent	Great extent
14O	Use program evaluation results for program improvement by sharing results with evaluation stakeholders, revising program work plans, and revising subsequent annual evaluation plans	0	0	0	0	0	0
14P	Develop dissemination documents to share lessons learned	0	0	0	0	0	0
14Q	Participate in evaluation and dissemination implementation science-driven studies to contribute to viable models for sustainable comprehensive cancer control	0	0	0	0	0	0

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

15. Of the TTA you participated in between [insert start date of response period] and [insert end date of response period], which TTA activities had the most impact on your ability to conduct the activities listed above? Select all that apply.

- 1, FLCC Refresher Sessions
- 2, Webinars
- 3, Cancer screening briefs
- 4, Online Academy Ambassador Programs
- 5, GWCC Online Academy
- 6, GWCC Online Academy Ambassador Program
- 7, Micro-learning modules through the ACS Coalition University
- 8, Cancer Awareness Toolkits
- 9, In-person training/workshops or TA
- 10, Micro-learning modules
- 11, Networking sessions
- 12, Communities of Practice or Learning Communities, please specify: {15A}
- 77, Other TTA activity type, please specify: {15B}

[DISPLAY ONLY IF 15.12=1]

15A. Please specify in which Communities of Practice you participated:
[TEXT BOX]

[DISPLAY ONLY IF 15.77=1]

15B. Please specify "Other" TTA activity type:
[TEXT BOX]

Section 6. TTA Influence on Recipient Organizational Capacity

SECTION 6. TTA Influence on Recipient Organizational Capacity

With the next set of questions, we would like you to share your perceptions about the extent to which TTA received from NCCCP TTA providers influenced **your program's capacity** to implement your comprehensive cancer control plan. Please respond based on your observations and experiences.

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

16. To what extent has the TTA you received between [insert start date of response period] and [insert end date of response period] contributed to *your program's* ability to have:

		88	0	1	2	3
		Don't know	Not at all	Small extent	Moderate extent	Great extent
16A	Improved coalition partnerships	0	0	0	0	0
16B	Expanded reach to populations of focus	0	0	0	0	0
16C	Enhanced organizational sustainability	0	0	0	0	0
16D	Improved overall programmatic capacity	0	0	0	0	0
16E	Improved implementation of evidence-based interventions to address cancer burden	0	0	0	0	0
16F	Enhanced monitoring and evaluation of program activities and impact	0	0	0	0	0
16G	Increased capacity to utilize secondary data to inform program priorities and activities	0	0	0	0	0
16H	Other programmatic capacity, please specify: {16I}	0	0	0	0	0

[DISPLAY ONLY IF 16H=1; 2; OR 3]

16I. Please specify "Other programmatic capacity":
[TEXT BOX]

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

17. Of the TTA you participated in between [insert start date of response period] and [insert end date of response period], which TTA activities had the most impact on your program's capabilities? Select all that apply.

- 1, FLCC Refresher Sessions
- 2, Webinars
- 3, Cancer screening briefs
- 4, Online Academy Ambassador Programs
- 5, GWCC Online Academy
- 6, GWCC Online Academy Ambassador Program
- 7, Micro-learning modules through the ACS Coalition University
- 8, Cancer Awareness Toolkits
- 9, In-person training/workshops or TA
- 10, Micro-learning modules
- 11, Networking sessions
- 12, Communities of Practice or Learning Communities, please specify: {17A}
- 77, Other TTA activity type, please specify: {17B}

[DISPLAY ONLY IF 17.12=1]

17A. Please specify in which Communities of Practice staff or partners of your comprehensive cancer control program participated:
[TEXT BOX]

[DISPLAY ONLY IF 17.77=1]

17B. Please specify "Other" TTA activity type:
[TEXT BOX]

Section 7. Satisfaction with TTA Received

SECTION 7. Satisfaction with TTA Received

The purpose of the following questions is to collect information on your perceptions of TTA received from NCCCP TTA providers.

The following four questions pertain to your satisfaction with various qualities of the TTA you received between [insert start date of response period] and [insert end date of response period].

18. Please rate the relevance of the TTA you received between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Not relevant	Somewhat relevant	Relevant	Highly relevant
Webinars [DISPLAY IF 10=1]	0	0	0	0	0
Emails or newsletters [DISPLAY IF 10=2]	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Not relevant	Somewhat relevant	Relevant	Highly relevant
In-person trainings [DISPLAY IF 10=3]	0	0	0	0	0
Asynchronous trainings [DISPLAY IF 10=4]	0	0	0	0	0
One-on-one calls [DISPLAY IF 10=5]	0	0	0	0	0
Small group/peer-to-peer learning [DISPLAY IF 10=6]	0	0	0	0	0
Toolkits & briefs [DISPLAY IF 10=7]	0	0	0	0	0
Site visits [DISPLAY IF 10=8]	0	0	0	0	0
Communities of Practice/Learning Communities [DISPLAY IF 10=9]	0	0	0	0	0
Online resources (<i>pipe in 10A</i>) [DISPLAY IF 10=10]	0	0	0	0	0
Other TTA (<i>pipe in 10B</i>) [DISPLAY IF 10=77]	0	0	0	0	0

19. Please rate the usefulness of the TTA you received between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Not useful	Somewhat useful	Useful	Very useful
Webinars [DISPLAY IF 10=1]	0	0	0	0	0
Emails or newsletters [DISPLAY IF 10=2]	0	0	0	0	0
In-person trainings [DISPLAY IF 10=3]	0	0	0	0	0
Asynchronous trainings [DISPLAY IF 10=4]	0	0	0	0	0
One-on-one calls [DISPLAY IF 10=5]	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Not useful	Somewhat useful	Useful	Very useful
Small group/peer-to-peer learning [DISPLAY IF 10=6]	0	0	0	0	0
Toolkits & briefs [DISPLAY IF 10=7]	0	0	0	0	0
Site visits [DISPLAY IF 10=8]	0	0	0	0	0
Communities of Practice/Learning Communities [DISPLAY IF 10=9]	0	0	0	0	0
Online resources (<i>pipe in 10A</i>) [DISPLAY IF 10=10]	0	0	0	0	0
Other TTA (<i>pipe in 10B</i>) [DISPLAY IF 10=77]	0	0	0	0	0

20. Please rate the quality of the TTA you received between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Poor quality	Fair quality	Good quality	Excellent quality
Webinars [DISPLAY IF 10=1]	0	0	0	0	0
Emails or newsletters [DISPLAY IF 10=2]	0	0	0	0	0
In-person trainings [DISPLAY IF 10=3]	0	0	0	0	0
Asynchronous trainings [DISPLAY IF 10=4]	0	0	0	0	0
One-on-one calls [DISPLAY IF 10=5]	0	0	0	0	0
Small group/peer-to-peer learning [DISPLAY IF 10=6]	0	0	0	0	0
Toolkits & briefs [DISPLAY IF 10=7]	0	0	0	0	0
Site visits [DISPLAY IF 10=8]	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Poor quality	Fair quality	Good quality	Excellent quality
Communities of Practice/Learning Communities [DISPLAY IF 10=9]	0	0	0	0	0
Online resources (<i>pipe in 10A</i>) [DISPLAY IF 10=10]	0	0	0	0	0
Other TTA (<i>pipe in 10B</i>) [DISPLAY IF 10=77]	0	0	0	0	0

[PAGE BREAK]

The following four questions pertain to your satisfaction with various qualities of the communication about the TTA offerings between [insert start date of response period] and [insert end date of response period].

21. Please rate your satisfaction with the timing of the communication about the TTA offerings between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Not satisfied	Somewhat satisfied	Satisfied	Very satisfied
Webinars [DISPLAY IF 10=1]	0	0	0	0	0
Emails or newsletters [DISPLAY IF 10=2]	0	0	0	0	0
In-person trainings [DISPLAY IF 10=3]	0	0	0	0	0
Asynchronous trainings [DISPLAY IF 10=4]	0	0	0	0	0
One-on-one calls [DISPLAY IF 10=5]	0	0	0	0	0
Small group/peer-to-peer learning [DISPLAY IF 10=6]	0	0	0	0	0
Toolkits & briefs [DISPLAY IF 10=7]	0	0	0	0	0
Site visits [DISPLAY IF 10=8]	0	0	0	0	0
Communities of	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Not satisfied	Somewhat satisfied	Satisfied	Very satisfied
Practice/Learning Communities [DISPLAY IF 10=9]					
Online resources (<i>pipe in 10A</i>) [DISPLAY IF 10=10]	0	0	0	0	0
Other TTA (<i>pipe in 10B</i>) [DISPLAY IF 10=77]	0	0	0	0	0

22. Please rate your satisfaction with the *frequency* of the communication about the TTA offerings between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Not satisfied	Somewhat satisfied	Satisfied	Very satisfied
Webinars [DISPLAY IF 10=1]	0	0	0	0	0
Emails or newsletters [DISPLAY IF 10=2]	0	0	0	0	0
In-person trainings [DISPLAY IF 10=3]	0	0	0	0	0
Asynchronous trainings [DISPLAY IF 10=4]	0	0	0	0	0
One-on-one calls [DISPLAY IF 10=5]	0	0	0	0	0
Small group/peer-to-peer learning [DISPLAY IF 10=6]	0	0	0	0	0
Toolkits & briefs [DISPLAY IF 10=7]	0	0	0	0	0
Site visits [DISPLAY IF 10=8]	0	0	0	0	0
Communities of Practice/Learning Communities [DISPLAY IF 10=9]	0	0	0	0	0
Online resources (<i>pipe in 10A</i>) [DISPLAY IF 10=10]	0	0	0	0	0
Other TTA (<i>pipe in 10B</i>)	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Not satisfied	Somewhat satisfied	Satisfied	Very satisfied
[DISPLAY IF 10=77]					

23. Please rate your satisfaction with the *quality* of the communication about the TTA offerings between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Not satisfied	Somewhat satisfied	Satisfied	Very satisfied
Webinars [DISPLAY IF 10=1]	0	0	0	0	0
Emails or newsletters [DISPLAY IF 10=2]	0	0	0	0	0
In-person trainings [DISPLAY IF 10=3]	0	0	0	0	0
Asynchronous trainings [DISPLAY IF 10=4]	0	0	0	0	0
One-on-one calls [DISPLAY IF 10=5]	0	0	0	0	0
Small group/peer-to-peer learning [DISPLAY IF 10=6]	0	0	0	0	0
Toolkits & briefs [DISPLAY IF 10=7]	0	0	0	0	0
Site visits [DISPLAY IF 10=8]	0	0	0	0	0
Communities of Practice/Learning Communities [DISPLAY IF 10=9]	0	0	0	0	0
Online resources (<i>pipe in 10A</i>) [DISPLAY IF 10=10]	0	0	0	0	0
Other TTA (<i>pipe in 10B</i>) [DISPLAY IF 10=77]	0	0	0	0	0

[PAGE BREAK]

The following four questions pertain to your satisfaction with various qualities of the *topics* you received TTA for between [insert start date of response period] and [insert end date of response period].

*Must provide answer

[ASK IF 11=1, ..., 40 as described below]

24. Please rate the relevance of the topics you received TTA for between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Not relevant	Somewhat relevant	Relevant	Highly relevant
Coalition functioning [DISPLAY IF 11=1]	0	0	0	0	0
Primary prevention: Alcohol [DISPLAY IF 11=2]	0	0	0	0	0
Primary prevention: Environmental exposure [DISPLAY IF 11=3]	0	0	0	0	0
Primary prevention: Hepatitis B transmission or vaccination [DISPLAY IF 11=4]	0	0	0	0	0
Primary prevention: Human papillomavirus (HPV) [DISPLAY IF 11=5]	0	0	0	0	0
Primary prevention: Nutrition [DISPLAY IF 11=6]	0	0	0	0	0
Primary prevention: Obesity/overweight [DISPLAY IF 11=7]	0	0	0	0	0
Primary prevention: Physical activity [DISPLAY IF 11=8]	0	0	0	0	0
Primary prevention: Radon [DISPLAY IF 11=9]	0	0	0	0	0
Primary prevention: Sun/UV exposure [DISPLAY IF 11=10]	0	0	0	0	0
Primary prevention: Tobacco [DISPLAY IF 11=11]	0	0	0	0	0
Primary prevention: Other types of risk or protective factors (<i>pipe in 11A</i>) [DISPLAY ONLY IF 11.12=1]	0	0	0	0	0
Screening and early detection: General cancer [DISPLAY IF 11=13]	0	0	0	0	0
Screening and early detection: Breast cancer [DISPLAY IF 11=14]	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Not relevant	Somewhat relevant	Relevant	Highly relevant
Screening and early detection: Cervical cancer [DISPLAY IF 11=15]	0	0	0	0	0
Screening and early detection: Colorectal cancer (CRC) [DISPLAY IF 11=16]	0	0	0	0	0
Screening and early detection: Gynecological cancers [DISPLAY IF 11=17]	0	0	0	0	0
Screening and early detection: HPV-related cancers [DISPLAY IF 11=18]	0	0	0	0	0
Screening and early detection: Liver cancer [DISPLAY IF 11=19]	0	0	0	0	0
Screening and early detection: Lung cancer [DISPLAY IF 11=20]	0	0	0	0	0
Screening and early detection: Oral cancer [DISPLAY IF 11=21]	0	0	0	0	0
Screening and early detection: Ovarian cancer [DISPLAY IF 11=22]	0	0	0	0	0
Screening and early detection: Prostate cancer [DISPLAY IF 11=23]	0	0	0	0	0
Screening and early detection: Skin cancer [DISPLAY IF 11=24]	0	0	0	0	0
Screening and early detection: Other types of cancer (<i>pipe in 11B</i>) [DISPLAY ONLY IF 11.25=1]	0	0	0	0	0
Survivorship: Survivors [DISPLAY IF 11=26]	0	0	0	0	0
Survivorship: Caregivers, family members, support system [DISPLAY IF 11=27]	0	0	0	0	0
Survivorship: Palliative care and hospice [DISPLAY IF 11=42]	0	0	0	0	0
Policy, systems, and environmental change strategies [DISPLAY IF 11=28]	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Not relevant	Somewhat relevant	Relevant	Highly relevant
Psychosocial and behavioral change [DISPLAY IF 11=29]	0	0	0	0	0
Community clinical linkages [DISPLAY IF 11=30]	0	0	0	0	0
Population reach strategies [DISPLAY IF 11=31]	0	0	0	0	0
Rural populations [DISPLAY IF 11=43]	0	0	0	0	0
Health for all [DISPLAY IF 11=32]	0	0	0	0	0
Evaluation and quality improvement [DISPLAY IF 11=33]	0	0	0	0	0
Establishment and building sustainable partnerships [DISPLAY IF 11=34]	0	0	0	0	0
Maintaining partnerships [DISPLAY IF 11=35]	0	0	0	0	0
Building sustainable programs [DISPLAY IF 11=36]	0	0	0	0	0
Using secondary (i.e., surveillance) data to inform program planning [DISPLAY IF 11=37]	0	0	0	0	0
Using secondary (i.e., surveillance) data to inform program evaluation [DISPLAY IF 11=38]	0	0	0	0	0
Addressing high programmatic staff turnover [DISPLAY IF 11=39]	0	0	0	0	0
Workforce development [DISPLAY IF 11=40]	0	0	0	0	0
Stigma [DISPLAY IF 11=41]	0	0	0	0	0
Other topic (<i>pipe in 11C</i>) [DISPLAY ONLY IF 11.77=1]	0	0	0	0	0

[ASK IF 11=1, ..., 40 as described in 24]

25. Please rate the usefulness of the topics you received TTA for between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Not useful	Somewhat useful	Useful	Very useful
Coalition functioning	0	0	0	0	0
Primary prevention: Alcohol	0	0	0	0	0
Primary prevention: Environmental exposure	0	0	0	0	0
Primary prevention: Hepatitis B transmission or vaccination	0	0	0	0	0
Primary prevention: Human papillomavirus (HPV)	0	0	0	0	0
Primary prevention: Nutrition	0	0	0	0	0
Primary prevention: Obesity/overweight	0	0	0	0	0
Primary prevention: Physical activity	0	0	0	0	0
Primary prevention: Radon	0	0	0	0	0
Primary prevention: Sun/UV exposure	0	0	0	0	0
Primary prevention: Tobacco	0	0	0	0	0
Primary prevention: Other types of risk or protective factors (<i>pipe in 11A</i>) [DISPLAY ONLY IF 11.12=1]	0	0	0	0	0
Screening and early detection: General cancer	0	0	0	0	0
Screening and early detection: Breast cancer	0	0	0	0	0
Screening and early detection: Cervical cancer	0	0	0	0	0
Screening and early detection: Colorectal cancer (CRC)	0	0	0	0	0
Screening and early detection: Gynecological cancers	0	0	0	0	0
Screening and early detection: HPV-related cancers	0	0	0	0	0
Screening and early detection: Liver cancer	0	0	0	0	0
Screening and early detection: Lung cancer	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Not useful	Somewhat useful	Useful	Very useful
Screening and early detection: Oral cancer	0	0	0	0	0
Screening and early detection: Ovarian cancer	0	0	0	0	0
Screening and early detection: Prostate cancer	0	0	0	0	0
Screening and early detection: Skin cancer	0	0	0	0	0
Screening and early detection: Other types of cancer (<i>pipe in 11B</i>) [DISPLAY ONLY IF 11.25=1]	0	0	0	0	0
Survivorship: Survivors	0	0	0	0	0
Survivorship: Caregivers, family members, support system	0	0	0	0	0
Survivorship: Palliative care and hospice	0	0	0	0	0
Policy, systems, and environmental change strategies	0	0	0	0	0
Psychosocial and behavioral change	0	0	0	0	0
Community clinical linkages	0	0	0	0	0
Population reach strategies	0	0	0	0	0
Rural populations	0	0	0	0	0
Health for all	0	0	0	0	0
Evaluation and quality improvement	0	0	0	0	0
Establishment and building sustainable partnerships	0	0	0	0	0
Maintaining partnerships	0	0	0	0	0
Building sustainable programs	0	0	0	0	0
Using secondary (i.e., surveillance) data to inform program planning	0	0	0	0	0
Using secondary (i.e., surveillance) data to inform program evaluation	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Not useful	Somewhat useful	Useful	Very useful
Addressing high programmatic staff turnover	0	0	0	0	0
Workforce development	0	0	0	0	0
Stigma	0	0	0	0	0
Other topic (<i>pipe in 11C</i>) [DISPLAY ONLY IF 11.77=1]	0	0	0	0	0

[ASK IF 11=1, ..., 40 as described in 24]

26. Please rate the quality of the topics you received TTA for between [insert start date of response period] and [insert end date of response period].

	77	1	2	3	4
	N/A	Poor quality	Fair quality	Good quality	Excellent quality
Coalition functioning	0	0	0	0	0
Primary prevention: Alcohol	0	0	0	0	0
Primary prevention: Environmental exposure	0	0	0	0	0
Primary prevention: Hepatitis B transmission or vaccination	0	0	0	0	0
Primary prevention: Human papillomavirus (HPV)	0	0	0	0	0
Primary prevention: Nutrition	0	0	0	0	0
Primary prevention: Obesity/overweight	0	0	0	0	0
Primary prevention: Physical activity	0	0	0	0	0
Primary prevention: Radon	0	0	0	0	0
Primary prevention: Sun/UV exposure	0	0	0	0	0
Primary prevention: Tobacco	0	0	0	0	0
Primary prevention: Other types of risk or protective factors (<i>pipe in 11A</i>) [DISPLAY ONLY IF 11.12=1]	0	0	0	0	0
Screening and early detection: General cancer	0	0	0	0	0
Screening and early detection:	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Poor quality	Fair quality	Good quality	Excellent quality
Breast cancer					
Screening and early detection: Cervical cancer	0	0	0	0	0
Screening and early detection: Colorectal cancer (CRC)	0	0	0	0	0
Screening and early detection: Gynecological cancers	0	0	0	0	0
Screening and early detection: HPV-related cancers	0	0	0	0	0
Screening and early detection: Liver cancer	0	0	0	0	0
Screening and early detection: Lung cancer	0	0	0	0	0
Screening and early detection: Oral cancer	0	0	0	0	0
Screening and early detection: Ovarian cancer	0	0	0	0	0
Screening and early detection: Prostate cancer	0	0	0	0	0
Screening and early detection: Skin cancer	0	0	0	0	0
Screening and early detection: Other types of cancer (<i>pipe in 11B</i>) [DISPLAY ONLY IF 11.25=1]	0	0	0	0	0
Survivorship: Survivors	0	0	0	0	0
Survivorship: Caregivers, family members, support system	0	0	0	0	0
Survivorship: Palliative care and hospice	0	0	0	0	0
Policy, systems, and environmental change strategies	0	0	0	0	0
Psychosocial and behavioral change	0	0	0	0	0
Community clinical linkages	0	0	0	0	0
Population reach strategies	0	0	0	0	0
Rural populations	0	0	0	0	0

*Must provide answer

	77	1	2	3	4
	N/A	Poor quality	Fair quality	Good quality	Excellent quality
Health for all	0	0	0	0	0
Evaluation and quality improvement	0	0	0	0	0
Establishment and building sustainable partnerships	0	0	0	0	0
Maintaining partnerships	0	0	0	0	0
Building sustainable programs	0	0	0	0	0
Using secondary (i.e., surveillance) data to inform program planning	0	0	0	0	0
Using secondary (i.e., surveillance) data to inform program evaluation	0	0	0	0	0
Addressing high programmatic staff turnover	0	0	0	0	0
Workforce development	0	0	0	0	0
Stigma	0	0	0	0	0
Other topic (<i>pipe in 11C</i>) [DISPLAY ONLY IF 11.77=1]	0	0	0	0	0

[PAGE BREAK]

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

27. Which approaches to providing TTA, if any, made the TTA received between [insert start date of response period] and [insert end date of response period] successful? Select all that apply.

- 1, Relevance of the content to my work (e.g., population(s) of focus, rurality)
- 2, Quality of the instruction/facilitation
- 3, Expertise of the trainers/presenters
- 4, Interactive nature of the sessions
- 5, Practical, actionable information provided
- 6, Flexibility of online/virtual delivery methods
- 7, Opportunities for peer-to-peer learning
- 8, Availability of follow-up support
- 9, Clear and concise materials
- 10, Timeliness of the TTA (addresses current needs)
- 11, Customization to our specific organizational needs
- 12, Hands-on exercises or case studies

*Must provide answer

- 13, Adequate time for questions and discussion
- 14, Post-TTA resources provided
- 15, Accessibility of the materials provided for individuals with visual, auditory, cognitive, and motor impairments (e.g., closed captions, audio, preferred language)
- 16, Convenient scheduling
- 17, TTA provider follow-through
- 18, Length of individual TTA engagement activities
- 77, Other, please specify: {27A}
- 0, None of the above, the TTA that I received was not successful [EXCLUSIVE]

[ASK IF 27(77)=1]

27A. Please specify "other" TTA approach:

[TEXT BOX]

[ASK IF 10=1,2,3,4,5,6,7,8, 9, 10, 11]

28. What, if anything, would have made the TTA you received between [insert start date of response period] and [insert end date of response period] more useful for your NCCCP-funded work?

[TEXT BOX]

[ASK IF 8.1 = YES, 8.2 = YES, OR 8.3=YES]

29. In which of the following topics or subject areas would you like more training? Select all that apply.

- 1, Coalition functioning
- 2, Primary prevention: Alcohol
- 3, Primary prevention: Environmental exposure
- 4, Primary prevention: Hepatitis B transmission or vaccination
- 5, Primary prevention: Human papillomavirus (HPV)
- 6, Primary prevention: Nutrition
- 7, Primary prevention: Obesity/overweight
- 8, Primary prevention: Physical activity
- 9, Primary prevention: Radon
- 10, Primary prevention: Sun/UV exposure
- 11, Primary prevention: Tobacco
- 12, Primary prevention: Other types of risk or protective factors, please specify: {29A}
- 13, Screening and early detection: General cancer
- 14, Screening and early detection: Breast cancer
- 15, Screening and early detection: Cervical cancer
- 16, Screening and early detection: Colorectal cancer (CRC)
- 17, Screening and early detection: Gynecological cancer
- 18, Screening and early detection: HPV-related cancers
- 19, Screening and early detection: Liver cancer
- 20, Screening and early detection: Lung cancer
- 21, Screening and early detection: Oral cancer
- 22, Screening and early detection: Ovarian cancer

- 23, Screening and early detection: Prostate cancer
- 24, Screening and early detection: Skin cancer
- 25, Screening and early detection: Other types of cancer, please specify: {29B}
- 26, Survivorship: Survivors
- 27, Survivorship: Caregivers, family members, support system
- 42, Survivorship: Palliative care and hospice
- 28, Policy, systems, and environmental change strategies
- 29, Psychosocial and behavioral change
- 30, Community clinical linkages
- 31, Population reach strategies
- 43, Rural populations (e.g., improving access, adapting programs or content, addressing rural-specific barriers)
- 32, Health for all
- 33, Evaluation and quality improvement
- 34, Establishing and building sustainable partnerships
- 35, Maintaining partnerships
- 36, Building sustainable programs
- 37, Using secondary (i.e., surveillance) data to inform program planning
- 38, Using secondary (i.e., surveillance) data to inform program evaluation
- 39, Addressing high programmatic staff turnover (e.g., retention strategies, succession planning)
- 40, Workforce development
- 41, Stigma
- 77, Other topics, please specify: {29C}
- 0, No other topics or subjects, I am satisfied with the topics or subject areas of training available

[EXCLUSIVE]

[DISPLAY ONLY IF 29.12=1]

29A. Please specify the types of risk or protective factors that you would like more training on as it relates to "Primary prevention: Other types of risk or protective factors":

[TEXT BOX]

[DISPLAY ONLY IF 29.25=1]

29B. Please specify the types of cancer that you would like more training on as it relates to "Screening and early detection: Other types of cancer":

[TEXT BOX]

[DISPLAY ONLY IF 29.77=1]

29C. Please specify "Other" TTA topics that you would like more training on:

[TEXT BOX]

Closing

[ASK ALL]

Closing

30. Those are all of our questions for you. If there is anything else that you'd like to share about the TTA offerings, please feel free to provide that information here.

[TEXT BOX]

Thank you for your participation! **Be sure to click "Submit" before you go.**

END.

Thank you for your participation!

If you have any questions about this assessment, please contact the ICF NCCCP TTA Evaluation Team at nccpptta-evaluation@icf.com.